BTG plc (BTG) Stock Rating Reaffirmed by Deutsche Bank AG

BTG plc (LON:BTG)‘s stock had its “buy” rating restated by stock analysts at Deutsche Bank AG in a note issued to investors on Friday. They presently have a GBX 775 ($10.28) price objective on the stock. Deutsche Bank AG’s price target suggests a potential upside of 8.70% from the stock’s previous close.

Several other brokerages also recently issued reports on BTG. Shore Capital reissued a “not rated” rating on shares of BTG plc in a report on Thursday, July 13th. Numis Securities Ltd reissued a “buy” rating and issued a GBX 900 ($11.94) price target on shares of BTG plc in a report on Wednesday, June 14th. J P Morgan Chase & Co reissued a “neutral” rating on shares of BTG plc in a report on Monday, September 18th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 800 ($10.61) price target on shares of BTG plc in a report on Wednesday, August 30th. Finally, Peel Hunt reissued a “hold” rating and issued a GBX 680 ($9.02) price target on shares of BTG plc in a report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. BTG plc currently has a consensus rating of “Buy” and an average price target of GBX 780.33 ($10.35).

BTG plc (LON BTG) opened at 713.00 on Friday. The stock has a 50 day moving average price of GBX 682.42 and a 200-day moving average price of GBX 662.79. BTG plc has a 12-month low of GBX 528.36 and a 12-month high of GBX 738.50. The firm’s market cap is GBX 2.75 billion.

COPYRIGHT VIOLATION WARNING: This article was first reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/10/08/btg-plc-btg-stock-rating-reaffirmed-by-deutsche-bank-ag.html.

BTG plc Company Profile

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG plc (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply